Grant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Grant GrossMendelsohn LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 66.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,156 shares of the company's stock after selling 26,143 shares during the period. Grant GrossMendelsohn LLC's holdings in Tarsus Pharmaceuticals were worth $654,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $25,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $44,000. Amalgamated Bank grew its stake in Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after acquiring an additional 295 shares in the last quarter. Quarry LP bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $166,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $207,000. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TARS has been the subject of several research reports. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target for the company in a research report on Tuesday, May 27th. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target for the company. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Trading Down 4.8%

NASDAQ:TARS opened at $39.18 on Friday. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The firm has a 50 day moving average of $42.36 and a 200 day moving average of $47.07. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -14.35 and a beta of 0.80.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. As a group, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.